Status:
COMPLETED
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead Sponsor:
Acrotech Biopharma Inc.
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic l...
Detailed Description
OBJECTIVES: * Determine the maximum tolerated dose (MTD) of liposomal vincristine given with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). * Determine the ...
Eligibility Criteria
Inclusion
- Previously treated, relapsed or refractory ALL (including lymphoblastic lymphoma and Burkitt's subtypes) with measurable disease.
- Performance status ≤3 (ECOG).
- All ages are eligible. Those aged 12 years or older may be counted towards the MTD in the Phase I portion of the trial. Pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course).
- Adequate liver function (bilirubin ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal).
- Negative pregnancy test in females of childbearing potential.
- Patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements.
Exclusion
- Active serious infection not controlled by oral or intravenous antibiotics.
- Treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the Investigator.
- Concurrent treatment with other anti-cancer agents other than dexamethasone.
- Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the Principal Investigator. Lumbar puncture not required in asymptomatic patients.
- Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent Grade 2 or greater active neuropathy.
- History of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders).
- Prior history of hypersensitivity reactions to vincristine or any of the other components of VSLI.
- Pregnant and/or lactating women; or fertile men or women not willing to use contraception.
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00144963
Start Date
July 1 2002
End Date
August 1 2006
Last Update
December 12 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University
Atlanta, Georgia, United States, 30322
2
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
3
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030